PMID- 25527865
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20181202
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 33
IP  - 1
DP  - 2014 Dec 21
TI  - Detection of ALK protein expression in lung squamous cell carcinomas by 
      immunohistochemistry.
PG  - 109
LID - 10.1186/s13046-014-0109-2 [doi]
LID - 109
AB  - BACKGROUND: The echinoderm microtubule-associated protein-like 4 (EML4) gene and 
      the anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 
      5% of lung adenocarcimomas (ACA), leading to ALK overexpression and predicting 
      response to targeted therapy. To the present, few studies have been focused on 
      the expression of ALK protein in lung squamous cell carcinomas (SqCC). Only 
      several cases of lung SqCC were reported expression of ALK protein. No clinical 
      study has been published to explicit the relationship between ALK expression and 
      the response to targeted therapy in SqCC. METHODS: In this study, we analyzed ALK 
      protein expression with a specific rabbit monoclonal Ig antibody (D5F3 clone) in 
      207 cases of lung SqCC. The positive cases were confirmed with ALK fluorescence 
      in situ hybridization (FISH) and RT-PCR. RESULTS: We found that 3 out of 207 
      (1.4%) cases of lung SqCC were ALK positive detected by IHC staining, which were 
      confirmed by ALK FISH and RT-PCR. CONCLUSIONS: Our results indicate that ALK 
      protein expression is not a rare molecular event in SqCC. Although the frequency 
      of EML4-ALK rearrangements is lower in lung SqCC than that in lung 
      adenocarcinomas, their presence may provide additional treatment options in lung 
      SqCC. The response of SqCC patients with ALK expression to target therapy of 
      crizotinib should be explored.
FAU - Wang, Jiandong
AU  - Wang J
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. jd_wang@outlook.com.
FAU - Shen, Qin
AU  - Shen Q
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. jd_wang@outlook.com.
FAU - Shi, Qunli
AU  - Shi Q
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. shiqunli2005@aliyun.com.
FAU - Yu, Bo
AU  - Yu B
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. 9441698@qq.com.
FAU - Wang, Xuan
AU  - Wang X
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. wangxuan1130@163.com.
FAU - Cheng, Kai
AU  - Cheng K
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. chengkai_seu@126.com.
FAU - Lu, Guangming
AU  - Lu G
AD  - Department of Radiology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. cjr.luguangming@vip.163.com.
FAU - Zhou, Xiaojun
AU  - Zhou X
AD  - Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, 
      Nanjing, 210002, China. nanjing_81@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141221
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Carcinoma, Squamous Cell/*enzymology/genetics/pathology
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - *Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*enzymology/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/genetics
MH  - Receptor Protein-Tyrosine Kinases/*analysis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC4304180
EDAT- 2014/12/22 06:00
MHDA- 2015/12/15 06:00
PMCR- 2014/12/21
CRDT- 2014/12/22 06:00
PHST- 2014/11/02 00:00 [received]
PHST- 2014/12/05 00:00 [accepted]
PHST- 2014/12/22 06:00 [entrez]
PHST- 2014/12/22 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2014/12/21 00:00 [pmc-release]
AID - s13046-014-0109-2 [pii]
AID - 109 [pii]
AID - 10.1186/s13046-014-0109-2 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2014 Dec 21;33(1):109. doi: 10.1186/s13046-014-0109-2.